Jeannie Lee, CBC News Network Journalist Profile

Articles

Xist RNA binds select autosomal genes and depends on Repeat B to regulate their expression

2 weeks ago | elifesciences.org | Shengze Yao |Yesu Jeon |Barry Kesner |Jeannie Lee

eLife Assessment This valuable study addresses the potential roles of the master regulator of X chromosome inactivation, the Xist long non-coding RNA, in the regulation of autosomal genes. Using data from mouse cells, the authors propose that Xist can coat specific autosomal promoters, which in turn leads to the attenuation of their transcriptional activity. The evidence from individual genes is interesting, and the model aligns with recently published results from humans.
MetaDecorator: Generating Immersive Virtual Tours through Multimodality

Jan 27, 2025 | arxiv.org | Jeannie S. A |Yang Liu |Jeannie Lee |Haiwei Dong

arXiv:2501.16164 (cs) View PDF HTML (experimental) Subjects: Human-Computer Interaction (cs.HC); Artificial Intelligence (cs.AI); Emerging Technologies (cs.ET); Multimedia (cs.MM) Cite as: arXiv:2501.16164 [cs.HC] (or arXiv:2501.16164v1 [cs.HC] for this version) https://doi.org/10.48550/arXiv.2501.16164 Submission history From: Haiwei Dong [ view email] [v1] Mon, 27 Jan 2025 15:59:58 UTC (27,652 KB) Bibliographic Tools Bibliographic Explorer Toggle Bibliographic Explorer () Connected Papers...
Titan Announces Resignations of Directors

Oct 1, 2024 | morningstar.com | Jeannie Lee

TORONTO, Ontario, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that following its annual general meeting held on September 30, 2024 (the “Meeting”) and in accordance with Titan’s Majority Voting Policy (the “Voting Policy”), Anthony Giovinazzo, Cathy Steiner, Cary Vance and Paul Cataford have tendered to the Board of Directors (the “Board”) their resignations as directors of Titan (including Paul Cataford’s resignation as Board Chairman).
Conavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and Conavi

Sep 26, 2024 | morningstar.com | Jeannie Lee

TORONTO, Ontario, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that Conavi Medical Inc. (“Conavi”) has received the requisite shareholder approval required to proceed with the proposed combination of Titan and Conavi (the “Amalgamation”) in an all-stock transaction (the “Transaction”). This Transaction will constitute a reverse takeover of Titan.
Emergency Preparedness in Perioperative Services

Sep 25, 2024 | aornjournal.onlinelibrary.wiley.com | Jeannie Lee |Jeffrey E. Henne |Jack Welsh |Jeannie Lee MSN

Request Username Can't sign in? Forgot your username? Enter your email address below and we will send you your username If the address matches an existing account you will receive an email with instructions to retrieve your username
Re-analysis of CLAP data affirms PRC2 as an RNA binding protein

Sep 20, 2024 | biorxiv.org | Yongwoo Lee |Roy Blum |Michael Rosenberg |Jeannie Lee

AbstractUsing halo-tagged PRC2 and CLAP methodology, Guo et al. recently came to the conclusion that PRC2 is not an RNA binding protein (RBP). They suggested that previous findings are CLIP artifacts and argue that RNA cannot play a direct role in PRC2 regulation. Here, we perform a re-analysis of the authors raw datasets and come to contrary conclusions. First, CLAP demonstrates significant PRC2 enrichment throughout the transcriptome, including in XIST Repeat A (RepA) motif.
International Business Times

Sep 8, 2024 | markets.financialcontent.com | Jeannie Lee

TORONTO, Ontario, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that Titan management will host a webcast Q&A session on Thursday, September 19, 2024 at 5:00 pm ET in connection with filing and mailing of the management information circular, which was announced by press release issued on September 6, 2024. Titan will provide prepared remarks followed by a Q&A session.
Titan Amends Amalgamation Agreement with Conavi Medical Inc.

Jul 5, 2024 | morningstar.com | Jeannie Lee

TORONTO, Ontario, July 05, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a second amending agreement dated July 5, 2024 (the “Amending Agreement”), in respect of the previously announced amalgamation agreement dated March 17, 2024, as initially amended by an amending agreement on May 28, 2024 (collectively the “Amalgamation Agreement”) among Conavi Medical Inc. (“Conavi”), 1000824255 Ontario Inc.